StemCells, Inc. Announces Investigators From Two Clinical Trials to Present at Congress of Neurological Surgeons Annual Meeting

StemCells, Inc. Announces Investigators From Two Clinical Trials to Present at
Congress of Neurological Surgeons Annual Meeting

NEWARK, Calif., Oct. 17, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM), the leading stem cell company developing novel cell-based
therapeutics for disorders of the central nervous system, announced today that
investigators from two of the Company's clinical trials will make
presentations at the Congress of Neurological Surgeons Annual Meeting, which
will be held October 19-23 at the Moscone West Convention Center in San
Francisco, California.

The first presentation, scheduled for 2:36 p.m. Pacific Time on Monday,
October 21, will be given by Nathan Selden, MD, PhD, FACS, FAAP, who was
co-principal investigator in the Company's Phase I clinical study in neuronal
ceroid lipofuscinosis (NCL, also often referred to as Batten's disease) and
the four-year long-term observational study that followed. Dr. Selden will
present a summary of the results from the long-term follow up study, which
includes data from patients who are now more than five years after
transplantation of the Company's proprietary HuCNS-SC^® cells. Dr. Selden is
Campagna Chair of Pediatric Neurosurgery at Doernbecher Children's Hospital
and Oregon Health & Science University.

The second presentation, scheduled for 2:28 p.m. Pacific Time on Wednesday,
October 23, will be given by Raphael Guzman, MD, who is co-principal
investigator for the Company's Phase I/II study for chronic spinal cord injury
currently underway in Switzerland, Canada, and the United States.Dr. Guzman
will review interim results from that study, which to date has enrolled and
dosed seven of the 12 patients planned. Dr. Guzman is Chief of Pediatric
Neurosurgery and Vice Chair, Department of Neurosurgery at the University of

The Congress of Neurological Surgeons is the largest neurosurgical society in
the world and the global leader in neurosurgical education, serving to promote
health by advancing neurosurgery worldwide through innovation and excellence
in education.With more than 8,000 members worldwide, the Congress of
Neurological Surgeons provides global leadership in neurosurgery by inspiring
and facilitating scientific discovery and its translation into clinical
practice. The Annual Meeting is an essential event for medical professionals
and others seeking to learn about important advances in the field of
neurosurgery. For more information, visit

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization
of cell-based therapeutics and tools for use in stem cell-based research and
drug discovery. The Company's proprietary HuCNS-SC^® cells (purified human
neural stem cells) are currently in development as a potential treatment for a
broad range of central nervous system disorders.In a PhaseI clinical trial
in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in
children, the Company has shown preliminary evidence of progressive and
durable donor-derived myelination in all four patients transplanted with
HuCNS-SC cells.The Company is conducting a Phase I/II clinical trial in
chronic spinal cord injury in Switzerland, Canada and the United States, and
has reported positive interim data for the first three patients.The Company
is also conducting a Phase I/II clinical trial in dry age-related macular
degeneration (AMD) in the United States. In addition, the Company is pursuing
preclinical studies in Alzheimer's disease, with support from the California
Institute for Regenerative Medicine (CIRM).StemCells also markets stem cell
research products, including media and reagents, under the SC Proven^®
brand.Further information about StemCells is available at

Apart from statements of historical fact, the text of this press release
constitutes forward-looking statements within the meaning of the U.S.
securities laws, and is subject to the safe harbors created therein.These
statements include, but are not limited to, statements regarding the clinical
development of the Company's HuCNS-SC cells; the Company's ability to
commercialize drug discovery and drug development tools; and the future
business operations of the Company. These forward-looking statements speak
only as of the date of this news release. The Company does not undertake to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. Such statements reflect
management's current views and are based on certain assumptions that may or
may not ultimately prove valid. The Company's actual results may vary
materially from those contemplated in such forward-looking statements due to
risks and uncertainties to which the Company is subject, including those
described under the heading "Risk Factors" in the Company's Annual Report on
Form10-K for the year ended December 31, 2012 and in its subsequent reports
on Forms 10-Q and 8-K.

CONTACT: Rodney Young
         StemCells, Inc.
         Chief Financial Officer
         (510) 456-4128
         Ian Stone
         Russo Partners
         (619) 308-6541

company logo
Press spacebar to pause and continue. Press esc to stop.